Neoplastic pulmonary cytology : Why all the fuss over "NSCLC"?

Cancer Cytopathology

Volumn 119, Issue 1, 2011, Pages 3-4

  Cohen, Michael B ^a   Weydert, Jamie A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b MacFarland Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN;

CANCER CLASSIFICATION; CANCER MORPHOLOGY; CYTOLOGY; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NOTE; ONCOGENE K RAS; PRIORITY JOURNAL; CLASSIFICATION; EDITORIAL; LUNG TUMOR; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS;

EID: 79953134944     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20131     Document Type: Note

References (6)

1. Dimou A, Anagnostou V, Selbst M, et al. Specific objective histologic classification in non small cell lung cancer (NSCLC) cytology specimens. Cancer Cytopathol. 2010;118(5 suppl):362. Abstract 69.
2. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: Bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12:713-718.
3. Nicholson AG, Gonzalez D, Shah P, Pynegar MJ, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and p63, and EGFR mutation analysis. J Thorac Oncol. 2010;5:436-441.
4. Check W. Pathologists picking up the pace in NSCLC. CAP Today. 2010;24:1.
5. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010;46:1773-1780.
6. da Cunha Santas G, Tsao M-S, Kamel-Reid S, et al. Detection of EGFR and KRAS mutations in fine needle aspirates stored on Whatman FTA cards. Is this the tool for biobanking cytological samples in the molecular era? Cancer Cytopathol. 2010;118:450-456.